PROCEPT BioRobotics: Compelling Bet On Aquablation's GrowthSeeking Alpha · 1 day ago
PROCEPT BioRobotics Corp (PRCT) Shares Surge 4.0% -- What GF Score of 71 Tells InvestorsGuruFocus · 5 days ago
PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026GlobeNewsWire · Oct 12, 2026
PROCEPT BioRobotics (NASDAQ: PRCT) Investors: Securities Class Action Filed; Shareholders Should Contact Shareholders FoundationPRNewsWire · Oct 1, 2026
LAWSUIT ALERT: Investors who lost money with PROCEPT BioRobotics Corporation (NASDAQ: PRCT) shares should contact the Shareholders FoundationGlobeNewsWire · Sep 30, 2026
PROCEPT BioRobotics (NASDAQ:PRCT) & Varex Imaging (NASDAQ:VREX) Critical AnalysisDefense World · Sep 24, 2026PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH).
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 4, 2026 | -$0.46 | -$0.47 | Miss |
| Apr 29, 2026 | -$0.55 | -$0.56 | Miss |
| Feb 25, 2026 | -$0.32 | -$0.53 | Miss |
| Nov 4, 2025 | -$0.41 | -$0.38 | Beat |
| Aug 6, 2025 | -$0.41 | -$0.35 | Beat |
| Apr 24, 2025 | -$0.49 | -$0.45 | Beat |